Stoke Therapeutics counsel sells 1,457 shares at $29.95

Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported an open-market sale of Common Stock.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported an open-market sale of Common Stock. On June 16, 2026, he sold 1,457 shares at a price of $29.95 per share. Following this transaction, he directly holds 18,086 shares of Common Stock. The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025, indicating the trade was made under a pre-arranged schedule rather than as a discretionary market-timing decision.

Insider Trade Summary 10b5-1

Net Seller: 1,457 shares

Net Sell 1 txn

Insider Allan Jonathan

Role GENERAL COUNSEL & CORP SEC

Sold 1,457 shs ($44K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,457	$29.95	$44K

Holdings After Transaction: Common Stock — 18,086 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

Key Figures

Shares sold: 1,457 shares Sale price per share: $29.95 per share Shares held after transaction: 18,086 shares

3 metrics

Shares sold 1,457 shares Open-market sale on June 16, 2026

Sale price per share $29.95 per share Common Stock transaction on June 16, 2026

Shares held after transaction 18,086 shares Direct ownership after reported sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Stoke Therapeutics (STOK) report in this Form 4?

Stoke Therapeutics reported that General Counsel Jonathan Allan sold 1,457 shares of Common Stock in an open-market transaction at $29.95 per share on June 16, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Who is the insider involved in the latest Stoke Therapeutics (STOK) Form 4 filing?

The insider is Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics. He reported a single open-market sale of 1,457 shares of Common Stock and now directly holds 18,086 shares after the transaction disclosed.

How many Stoke Therapeutics (STOK) shares did the insider sell and at what price?

Jonathan Allan sold 1,457 shares of Stoke Therapeutics Common Stock at $29.95 per share. The transaction was an open-market sale reported on Form 4 and reflects a planned disposition under a Rule 10b5-1 trading arrangement.

How many Stoke Therapeutics (STOK) shares does the insider hold after this Form 4 trade?

After selling 1,457 shares, Jonathan Allan directly holds 18,086 shares of Stoke Therapeutics Common Stock. This remaining stake is reported in the Form 4 as his total direct ownership following the disclosed open-market sale.

Was the Stoke Therapeutics (STOK) insider sale made under a Rule 10b5-1 trading plan?

Yes. The footnote explains the sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025. Such plans pre-schedule trades, indicating the timing of this disposition was not a discretionary market-timing decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		S(1)		1,457	D	$29.95	18,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

	/s/ Jonathan Allan	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)